BioSpace News Archive

Study Will Evaluate the Performance of Teleflex Coronary Guidewires and Specialty Catheters in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions

TRV027 is a novel AT 1 receptor selective agonist with the potential to treat acute lung injury and ARDS Robust clinical development history with well-characterized PK and demonstrated safety in ~700 individuals -- CHESTERBROOK, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it ha

GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10th, 2020 at 1:20pm EDT, which is being held virtually. A live audio webcast of t

Analysis shows 30% of recommended surgeries could be better treated with non-surgical options

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He , Chairman & CEO will present an overview of the company and provide a business update at the Jefferies 2020 He

RenovoRx , an innovator in targeted cancer therapy, today announced the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for treating bile duct cancer ---- also

Nephros, Inc. (Nasdaq: NEPH ), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will be presenting at the upcoming Virtual Summer Summit on Tuesday, June 9 th at 10:55 AM ET. Andy Astor, COO & CFO of Nephros, will be giving the presentation and answering questions from i

VIVUS, Inc., a biopharmaceutical company, announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P., which holds a principal amount of approximately $170.2 million of the Company’s Convertible Senior Notes.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that recruiting has begun and the first patient has been e

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that dosing has commenced in the UK Government-backed Phase II clinical trial assessing bemcentinib in hospitalised COVID-19 patients.